4DMedical vs Telix Pharmaceuticals shares: which health innovator wins?

If you’re weighing up a buy between 4DMedical Ltd (ASX: 4DX) and Telix Pharmaceuticals Ltd (ASX: TLX), you’re comparing two ambitious Australian medical technology companies. Both are at the forefront of healthcare innovation, but their financial profiles and recent growth stories offer very different investment prospects. Let’s dig in to see how these two stack up.

The case for 4DMedical

4DMedical is breaking new ground in respiratory imaging. Its flagship CT:VQ software turns CT scans into detailed lung maps, giving doctors advanced tools for diagnosing diseases like pulmonary embolism and emphysema. The tech’s already in use at top US hospitals like Mayo Clinic and Stanford, with a recent European expansion thanks to its acquisition of Contextflow.

Looking at the numbers, 4DMedical carries a sizeable market cap of $2.07 billion but has yet to become profitable, posting negative earnings per share of -0.405. There’s no dividend on offer, and no price/earnings (P/E) ratio available yet; this signals it’s still firmly in growth mode. The year-to-date return sits at -14.5%, indicating a tough recent run for shareholders. This makes 4DX more of a high-risk, high-potential play, especially for those backing new technology looking to disrupt established medical imaging markets.

The case for Telix Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage biotech pushing the boundaries of cancer diagnostics and treatment. Its main product, Illuccix, has approvals from regulators including the TGA, FDA and Health Canada, making it a global force in prostate cancer imaging. Beyond Illuccix, Telix is running more than 20 clinical trials worldwide, chasing breakthroughs in cancer types ranging from kidney to brain to bone marrow.

Telix stands out for having already turned the corner into profitability. Its market cap dwarfs 4DMedical’s at $6.03 billion. Earnings per share are positive (0.099), which is rare for an ASX biotech this size. The company trades on an eye-watering P/E ratio of 118.40—sky-high, but not unusual for fast-growing pharmaceutical businesses. Like 4DMedical, Telix pays no dividend, pouring resources back into growth. But the real highlight is a stellar year-to-date share price return of 45.89%, signalling momentum.

Valuation comparison

Here’s a side-by-side look at the major valuation and fundamental metrics:

Metric	4DMedical (4DX)	Telix Pharmaceuticals (TLX)
Market Cap	$2.07 billion	$6.03 billion
P/E Ratio	N/A	118.40
Earnings per Share	-0.405	0.099
Dividend Yield	0.00%	0.00%
Year to Date Return	-14.50%	45.89%

There’s a clear gap in scale and financial maturity. Telix is both far larger by market cap and actually generating earnings, whereas 4DMedical is still burning through capital to develop its market. Neither pays a dividend, so both are pure growth plays.

Recent share price performance

Share prices can be volatile in the health tech sector, but the difference here is striking. As of the latest data (mid-September 2026), 4DMedical shares sit at $3.44, having dropped 14.5% year to date. Its weekly moves have often swung several percent either way, showing volatility without a clear upward momentum.

Telix, meanwhile, is on a tear. As of 15 September 2026, shares closed at $17.75 and are up a hefty 45.89% for the year. The stock has seen sharp daily moves—like an 8.63% gain on one recent day—but the overall trend has been strongly positive. Telix’s growth story is, at least so far, being rewarded by the market.

Which is the better buy?

Weighing up these two, my pick would be Telix Pharmaceuticals. The company has global regulatory runs on the board, it’s already doing solid revenue, and it’s delivered real profit. Yes, it does trade on a huge earnings multiple, but I’d see that as justified given the momentum: 45% year-to-date gains, and more than 20 clinical trials in the pipeline.

4DMedical clearly has exciting technology and major growth aspirations, but as of now, it’s loss-making and suffering negative share price performance.

In short: if I’m backing an Aussie health innovator today, I’d go with Telix.

The post 4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown appeared first on The Motley Fool Australia.

More reading

• Are Telix shares a buy after its big US FDA news?
• These 2 ASX healthcare shares just jumped up to 15%. Here’s why
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The S&P/ASX 200 Index (ASX: XJO) was back to the races this Wednesday, staging a slight recovery that took some of the edge off yesterday’s nasty fall. After a wild day of trading, which saw the markets dip into red territory a few times, investors were happy to leave the ASX 200 with a decent 0.28% rise by the time trading closed. That leaves the index at 8,696.5 points.

This happy hump day for the Australian markets followed a far less optimistic session on Wall Street last night.

The Dow Jones Industrial Average Index (DJX: .DJI) was still feeling blue, and dropped another 0.63%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) wasn’t any better, losing 0.78% of its value.

But let’s return to the local markets now and check out what was happening amongst the different ASX sectors today.

Winners and losers

The biggest losers this Wednesday were consumer staples shares. The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) had a shocker today, dumping 1.15% of its value.

Real estate investment trusts (REITs) also had a day to forget, with the S&P/ASX 200 A-REIT Index (ASX: XPJ) retreating 0.54%.

Financial stocks were on the nose too. The S&P/ASX 200 Financials Index (ASX: XFJ) was walked back 0.37% this session.

Our last losers were consumer discretionary shares, evidenced by the S&P/ASX 200 Consumer Discretionary Index (ASX: XDJ)’s 0.35% decline.

Let’s turn to the green sectors now. Leading the charge were energy stocks. The S&P/ASX 200 Energy Index (ASX: XEJ) rocketed 2.19% higher this hump day.

Gold shares had a party as well, with the All Ordinaries Gold Index (ASX: XGD) surging 1.48%.

Broader mining stocks didn’t miss out. The S&P/ASX 200 Materials Index (ASX: XMJ) soared up 1.28%.

Next came communications shares, illustrated by the S&P/ASX 200 Communication Services Index (ASX: XTJ)s 0.46% bounce.

Industrial stocks were also in that range. The S&P/ASX 200 Industrials Index (ASX: XNJ) added 0.36% to its total today.

Tech shares overcame some selling to close higher, with the S&P/ASX 200 Information Technology Index (ASX: XIJ) putting on 0.3%.

Utilities stocks didn’t miss out either. The S&P/ASX 200 Utilities Index (ASX: XUJ) saw itsvalue bumped by 0.28%.

Finally, healthcare shares got themselves over the line, as you can see by the S&P/ASX 200 Healthcare Index (ASX: XHJ)’s 1.5% surge.

Top 10 ASX 200 shares countdown

Gold stock Pantoro Gold Ltd (ASX: PNR) came in as our top stock today. Pantoro Gold shares jumped 9.3% to close at $2.82 a share. This came after Pantoro revealed some drilling results this morning, which may have excited investors.

Here’s how the other winners pulled up at the kerb:

ASX-listed company	Share price	Price change
Pantoro Gold Ltd (ASX: PNR)	$2.82	9.30%
Codan Ltd (ASX: CDA)	$48.94	7.51%
Alkane Resources Ltd (ASX: ALK)	$1.92	5.02%
Kingsgate Consolidated Ltd (ASX: KCN)	$5.36	4.69%
Bellevue Gold Ltd (ASX: BGL)	$1.58	4.29%
Austal Ltd (ASX: ASB)	$4.34	4.08%
Centuria Capital Group (ASX: CNI)	$1.33	3.92%
Infratil Ltd (ASX: IFT)	$11.32	3.57%
Reliance Worldwide Corporation Ltd (ASX: RWC)	$4.48	3.46%
Beach Energy Ltd (ASX: BPT)	$0.90	3.45%

Our top 10 shares countdown is a recurring end-of-day summary that shows which companies made big moves on the day. Check in at Fool.com.au after the weekday market closes to see which stocks make the countdown.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• The ASX 200 is finally rising. Is the sell-off running out of steam?
• Reliance shares surge to a 52-week high on $4.1 billion takeover deal
• Brookfield moves to acquire Reliance Worldwide Corporation at a 43% premium
• Infratil hikes earnings guidance as data centre growth accelerates
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Paladin Energy Ltd (ASX: PDN) shares are changing hands for $9.51 each in Wednesday afternoon trade.

That’s around a 0.5% decrease over the day, but after a line of share price declines, it means the shares have now tumbled around 17% over the past week alone.

For the year to date, Paladin Energy shares are down 6%, but they’re still 23% higher than a year ago.

What has happened to Paladin Energy shares over the past week?

There hasn’t been any price sensitive news out of the company over the past week to explain the latest sell-off. 

It looks like the decline is due to a number of factors, including geopolitical uncertainty, a drop in confidence about the outlook for ASX uranium shares, a company update, and its FY26 results late last month.

As a uranium production company that focuses on developing and operating uranium mines globally, Paladin Energy is highly sensitive to fluctuations in sentiment about uranium. 

The escalating conflict in the Middle East, higher inflation data, and concerns about more interest-rate rises has seen some investors reduce their exposure to riskier shares like Paladin Energy.

Elsewhere, Paladin Energy posted a note to the ASX last week confirming that JP Morgan Chase & Co, and its affiliates have ceased to be substantial holders in the company. It’s possible that the news may have spooked already concerned investors.

Meanwhile, the company posted its FY26 results late last month. The company posted a 71% year-on-year increase in sales revenue to US$304 million. Paladin Energy also reported a gross profit of US$52 million, up from a gross loss of US$26 million in FY25.

But while the uranium miner has shown improving operational metrics and turned a net profit, it also posted notable operating cash outflows. Paladin Energy ended the financial year with a net loss after tax of US$9.1 million, although that’s an improvement from the US$77 million net loss reported in FY25.

Are the uranium miner’s shares a buy, sell, or hold now?

Despite the confidence loss and recent sell off, it looks like brokers are still very bullish about the outlook for Paladin Energy shares over the next 12 months.

TradingView data shows that out of 15 analysts, 11 have a buy/strong buy rating on the shares and another 1 has a hold rating. Three more analysts have a strong sell rating on the shares.

The average $13.19 target price implies the shares could jump another 39% over the next year, at the time of writing. And some are even more bullish that the shares have the potential to climb 100% higher to $18.96.

The post Down 17% in a week: What has happened to Paladin Energy shares? appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Energy shares rose while the ASX 200 slumped last week. Here’s why
• Brokers are confident in the outlook for this uranium stock tipping 34% upside
• 5 things to watch on the ASX 200 on Wednesday
• 6 ASX shares tipped by brokers to rise 34% to 88%

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.